Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 370-374, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schumacher, G. E.
Right arrow Articles by Barr, J. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schumacher, G. E.
Right arrow Articles by Barr, J. T.
Related Collections
Right arrow Laboratory Management
Right arrow Therapeutic Drug Monitoring Conference
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 1998;44:370-374.)
© 1998 American Association for Clinical Chemistry, Inc.

TDM Conference

Total testing process applied to therapeutic drug monitoring: impact on patients' outcomes and economics

Gerald E. Schumachera, and Judith T. Barr

a Author for correspondence. Fax 617-373-2968,


Abstract

The Total Testing Process (TTP) refers to the sequence of 11 steps of laboratory testing, beginning with a clinical question prompted by the patient–clinician encounter and concluding with the impact of the test result on patient care. TTP when applied to therapeutic drug monitoring (TDM) emphasizes that TDM must be considered a process involving a series of steps and interrelated activities and not viewed simply as a numerical value for a serum drug concentration. TTP is also an ideal format for organizing and identifying the system-related and patient-centered variables used in outcomes assessment of TDM, as well as providing a template for collecting the cost data needed for economic analyses. Examples are provided for improving application of TDM by practitioners, clinical laboratories, and educators.




The following articles in journals at HighWire Press have cited this article:


Home page
 Nurs EthicsHome page
T. Nyrhinen, M. Hietala, P. Puukka, and H. Leino-Kilpi
Privacy and Equality in Diagnostic Genetic Testing
Nursing Ethics, May 1, 2007; 14(3): 295 - 308.
[Abstract] [PDF]

Home page
 ChestHome page
J. Li, J. N. Burzynski, Y.-A. Lee, D. Berg, C. R. Driver, R. Ridzon, and S. S. Munsiff
Use of Therapeutic Drug Monitoring for Multidrug-Resistant Tuberculosis Patients
Chest, December 1, 2004; 126(6): 1770 - 1776.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
G. D. Schiff, D. Klass, J. Peterson, G. Shah, and D. W. Bates
Linking Laboratory and Pharmacy: Opportunities for Reducing Errors and Improving Care
Arch Intern Med, April 28, 2003; 163(8): 893 - 900.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.